BioSpace News Archive

Drug Development

Argenx Raises $1.1B in Global Stock Offering Following Positive Phase II Data

The Netherlands-based immunology company said Wednesday it brought in $1.1 billion by selling more than two million shares in the U.S. and Europe.

July 18, 2023
·
3 min read
·
Tristan Manalac
Policy

Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen

Following the full approval of Leqembi, the CMS suggests expanding its coverage of beta-amyloid PET scans, which could improve the uptake of novel Alzheimer’s disease treatments.

July 18, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Neumora Races Toward Phase III with New Driver in the Hot Seat

Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.

July 18, 2023
·
2 min read
·
Kate Goodwin
Business

Pfizer Inks Potential $7B Deal with Flagship to Deepen Pipeline

Tuesday’s partnership will dig into Flagship’s deep ecosystem of companies and technologies to discover medicines in line with Pfizer’s core strategic areas.

July 18, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Novartis Cuts ‘Unique’ Obesity Drug After Poor Phase II Results

The company also terminated a Phase III trial of its TGFB inhibitor as a treatment for metastatic pancreatic ductal adenocarcinoma, though that drug will continue to be tested as a treatment for colorectal cancer.

July 18, 2023
·
2 min read
·
Connor Lynch
New Approaches to Cell and Gene Therapy Manufacturing Needed to Meet Demand

Next-gen biomanufacturers are particularly susceptible to the challenges inherent in manufacturing cell and gene therapies, risking getting derailed by unexpected costs for already-tight budgets.

July 18, 2023
·
3 min read
·
Lisa Munger
Business

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Pharming Group N.V. announces that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.

July 18, 2023
·
5 min read
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

Biophytis SA announced the conclusion of a master agreement for the production of the active compound in Sarconeos, Biophytis’ main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

July 18, 2023
·
5 min read
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its participation at the upcoming H.C.

July 18, 2023
·
3 min read
Business

Orexo Q2 2023 Interim Report

EBITDA of SEK 5.6 m (-32.5), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 30.3 m (11.4)

July 18, 2023
·
3 min read